Study identifies patients with obesity most likely to benefit from GLP-1-based treatment
· Medical Xpressby Sharon Theimer, Mayo Clinic
edited by Gaby Clark, reviewed by Andrew Zinin
Gaby Clark
Scientific Editor
Meet our editorial team
Behind our editorial process
Andrew Zinin
Chief Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add as preferred source
Why do some people lose substantial weight with GLP-1-based medications while others see more modest results? A Mayo Clinic study offers a potential answer by identifying a distinct biological subtype of obesity that responds especially well to tirzepatide, a medication that mimics two naturally occurring hormones involved in appetite and blood sugar regulation, moving the field closer to precision medicine for obesity.
The research, published in Gastroenterology, identified a subgroup of patients with obesity who produce lower levels of natural appetite-regulating hormones, experience faster stomach emptying and report greater hunger after meals. This is a subtype of the "hungry gut" obesity phenotype, characterized by an abnormal duration of fullness. People with hungry-gut obesity may eat normal portion sizes but snack more frequently.
These patients lost nearly twice as much weight after six months of tirzepatide treatment as patients with other obesity subtypes.
"Obesity is a complex disease driven by different biological mechanisms," said Dr. Andres Acosta, a gastroenterologist and obesity researcher at Mayo Clinic in Minnesota. "Our findings suggest we can begin identifying which patients are most likely to respond to specific therapies rather than treating obesity as a single disease."
Researchers studied 483 adults with obesity and found three different biological types of the disease. About 1 in 4 participants produced lower levels of GLP-1 and other hormones that help people feel full after eating. Patients in this group lost an average of 21.5% of their body weight after six months of treatment with tirzepatide, compared with 11.7% for patients in the other groups.
The findings support growing efforts to personalize obesity treatment using an individual's underlying biology rather than relying on a one-size-fits-all approach. Because obesity increases the risk of diabetes, heart disease, certain cancers and many other serious chronic conditions, identifying the right therapy sooner could improve long-term health outcomes.
The researchers also found that the reduced hormone levels were associated with decreased hormone production in the intestine rather than differences in the gut microbiome, providing new insight into the biology underlying this subtype of obesity.
The authors caution that prospective studies are needed before this approach can be incorporated into routine clinical practice, but these findings represent an important step toward more precise, individualized treatment for obesity.
Publication details
Alexander L. Ticho et al, A Subphenotype of Obesity With Reduced Enteroendocrine Glucagon-Like Peptide 1 Synthesis and Enhanced Tirzepatide Response, Gastroenterology (2026). DOI: 10.1053/j.gastro.2026.05.019
Journal information: Gastroenterology
Key medical concepts
Clinical categories
EndocrinologyWeight managementGastroenterology Provided by Mayo Clinic Who's behind this story?
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: Study identifies patients with obesity most likely to benefit from GLP-1-based treatment (2026, July 16) retrieved 17 July 2026 from https://medicalxpress.com/news/2026-07-patients-obesity-benefit-glp-based.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.